Dallal Abdelsayed, MD
Family Medicine · Highlands, TXNPI 1649345216
Payments from drug & device makers
Across 327 payments — averaging $2509.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$814K
- Novo Nordisk$1K
- Amgen$1K
- AstraZeneca$899
- Lilly USA, LLC$528
- Boehringer Ingelheim$453
- plus $2K from 24 others
Across 1 payment — averaging $6773.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$7K
What the payments were for
- Food & beverage$6,29298%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 11 | $814,099 |
| Novo Nordisk | 56 | $1,060 |
| Amgen(2 entities) | 48 | $1,000 |
| AstraZeneca | 48 | $899 |
| Lilly USA, LLC | 23 | $528 |
| Boehringer Ingelheim | 12 | $453 |
| Bayer | 16 | $431 |
| Astellas Pharma US Inc | 11 | $291 |
| AbbVie(2 entities) | 14 | $213 |
| GSK | 11 | $201 |
| Vanda Pharmaceuticals Inc. | 9 | $191 |
| Pfizer | 9 | $166 |
| Mylan Specialty L.p. | 6 | $134 |
| Sumitomo Pharma America, Inc. | 5 | $104 |
| Sunovion Pharmaceuticals Inc. | 10 | $103 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $84 |
| Eisai Inc. | 4 | $76 |
| Abbott | 4 | $73 |
| Ironwood Pharmaceuticals, Inc | 4 | $69 |
| Johnson & Johnson | 4 | $62 |
| Merck | 4 | $61 |
| Kowa Pharmaceuticals America, Inc. | 2 | $43 |
| Scilex Pharmaceuticals Inc. | 2 | $32 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Medtronic | 1 | $15 |
| IBSA Pharma Inc. | 1 | $15 |
| Zyla Life Sciences, Inc. | 1 | $14 |
| Lupin Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$820,491 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 72 | $96,376 |
| EliquisApixaban | 92 | $83,351 |
| FarxigaDapagliflozin Propanediol | 65 | $60,225 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $58,861 |
| JardianceEmpagliflozin | 56 | $56,484 |
| JanuviaSitagliptin Phosphate | 68 | $54,511 |
| OtezlaApremilast | 11 | $51,416 |
| TrulicityDulaglutide | 26 | $50,383 |
| RybelsusSemaglutide | 20 | $31,682 |
| LinzessLinaclotide | 30 | $31,004 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 38 | $28,849 |
| XareltoRivaroxaban | 30 | $18,783 |
| MounjaroTirzepatide | 12 | $16,955 |
| Repatha SureclickEvolocumab | 20 | $13,104 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 63 | $12,584 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,060 | $128,05792 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $899 | $98,729142 claims |
| PfizerEliquis | $166 | $83,35192 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $528 | $67,33838 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $453 | $65,61469 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $201 | $64,68076 claims |
| MerckJanuvia | $61 | $54,51168 claims |
| AmgenOtezla | $1,000 | $51,41611 claims |
| AbbVieLinzess, Synthroid | $213 | $33,18687 claims |
| Johnson & JohnsonXarelto | $62 | $18,78330 claims |
| Astellas Pharma US IncMyrbetriq | $291 | $11,77521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Highlands
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.